A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study

A nucleoside reverse transcriptase inhibitor (NRTI) backbone is a recommended component of standard highly active antiretroviral therapy (sHAART). However, long-term NRTI exposure can be limited by toxicities. NRTI class-sparing alternatives are warranted in select patient populations. This is a 48-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ofotokun, Ighovwerha, Sheth, Anandi N., Sanford, Sara E., Easley, Kirk A., Shenvi, Neeta, White, Kelly, Eaton, Molly E., Del Rio, Carlos, Lennox, Jeffrey L.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2012
Assuntos:
Clinical Trials/Clinical Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3448110/
https://ncbi.nlm.nih.gov/pubmed/22364141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2011.0336
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados